A real world study assessing the real-world clinical effectiveness of Lorlatinib in second or greater line setting as ALK TKI sequence treatment after failure of alectinib in patients with ALK+ Non-Small Cell Lung Cancer Japanese patients
Latest Information Update: 12 Oct 2021
At a glance
- Drugs Lorlatinib (Primary) ; Bevacizumab; Ceritinib; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2021 New trial record
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer